2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

GC cells

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

3

Fluorescent Dyes

1

Biochemical Assay Reagents

6

Peptides

4

Inhibitory Antibodies

3

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D1020
    7-Aminoactinomycin D
    5+ Cited Publications

    7-AAD

    		 DNA/RNA Synthesis Bacterial DNA Stain Antibiotic Infection Cancer
    7-Aminoactinomycin D (7-AAD) a cell-impermeant fluorescent DNA stain, is a potent RNA polymerase inhibitor. 7-Aminoactinomycin D selectively binds to GC regions of the DNA. 7-Aminoactinomycin D also has antibacterial effects .
    7-Aminoactinomycin D
  • HY-P99013
    Codrituzumab
    1 Publications Verification

    GC33; RO5137382

    		 Glycoprotein VI Cancer
    Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
    Codrituzumab
  • HY-111798A
    Heme Oxygenase-1-IN-1 hydrochloride
    10+ Cited Publications

    		 Reactive Oxygen Species (ROS) Cancer
    Heme Oxygenase-1-IN-1 (Compound 2) hydrochloride is a heme oxygenase 1 (HO-1) inhibitor with an IC50 of 0.25 μM .
    Heme Oxygenase-1-IN-1 hydrochloride
  • HY-W127512
    5β-Cholanic acid
    1 Publications Verification

    		 Drug Intermediate Others
    5β-Cholanic acid is a hydrophobic modifier used to modify polymer carriers. 5β-Cholanic acid can improve the acid stability, cell penetration efficiency and drug sustained release ability of nanocarriers, and optimize the oral effectiveness of delivered molecules. 5β-Cholanic acid can covalently bind to Glycol chitosan (GC) to form a GC-CA conjugate, which optimizes the hydrophobic anchoring ability of nanoparticles and enables them to be stably adsorbed on the surface of PLGA nanoparticles. Such nanoparticles can resist dissociation in the gastric acid environment and maintain positive charge to enhance endocytic uptake by intestinal epithelial cells (such as Caco-2 cells). 5β-Cholanic acid can be used in the development of drug delivery systems .
    5β-Cholanic acid
  • HY-W040129
    Chromomycin A3
    1 Publications Verification

    		 DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis Caspase Infection Neurological Disease Cancer
    Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg 2+. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .
    Chromomycin A3
  • HY-108741
    Plecanatide

    		Guanylate Cyclase Inflammation/Immunology Cancer
    Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis .
    Plecanatide
  • HY-111798
    Heme Oxygenase-1-IN-1
    10+ Cited Publications

    		 Reactive Oxygen Species (ROS) Cancer
    Heme Oxygenase-1-IN-1 (compound 2) is a potent heme oxygenase 1 (HO-1) inhibitor, with an IC50 of 0.25 μM. Heme Oxygenase-1-IN-1 can be used for cancer research .
    Heme Oxygenase-1-IN-1
  • HY-P0118B
    Disitertide diammonium
    15+ Cited Publications

    P144 diammonium

    		 TGF-beta/Smad PI3K Apoptosis Cancer
    Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer .
    Disitertide diammonium
  • HY-136684
    BrBzGCp2
    4 Publications Verification

    S-p-Bromobenzylglutathione cyclopentyl diester

    		 Glyoxalase (GLO) Neurological Disease Cancer
    BrBzGCp2 is a Glyoxalase 1 (GLO1) inhibitor, with a GC50 of 4.23 μM in HL-60 cells. BrBzGCp2 possesses antitumor and neuroprotective activity .
    BrBzGCp2
  • HY-W089645
    2,2,2-Trifluoro-N-methyl-N-(trimethylsilyl)acetamide
    1 Publications Verification

    N-Methyl-n-trimethylsilyltrifluoroacetamide

    		 Biochemical Assay Reagents Cancer
    2,2,2-Trifluoro-N-methyl-N-(trimethylsilyl)acetamide (N-Methyl-n-trimethylsilyltrifluoroacetamide) is an ester product commonly used for silylation reactions in analyticalchemistry. 2,2,2-Trifluoro-N-methyl-N-(trimethylsilyl)acetamide can be used in the derivatization step of metabolomics analysis with gas chromatography/mass spectrometry (GC/MS) or as a derivatization reagent in GC with flame ionization detection analysis. 2,2,2-Trifluoro-N-methyl-N-(trimethylsilyl)acetamide can be used in research for studying Tamoxifen (HY-13757A) resistant breast cancer cells and other disease pathways .
    2,2,2-Trifluoro-N-methyl-N-(trimethylsilyl)acetamide
  • HY-P0118
    Disitertide
    15+ Cited Publications

    P144

    		 TGF-beta/Smad PI3K Apoptosis Cancer
    Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer .
    Disitertide
  • HY-108628
    SU16f
    3 Publications Verification

    		 PDGFR Cancer
    SU16f is a potent and selective PDGFRβ inhibitor with IC50s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, VEGF-R2, FGF-R1, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .
    SU16f
  • HY-10498
    Lexibulin
    2 Publications Verification

    CYT-997

    		 Microtubule/Tubulin Reactive Oxygen Species (ROS) Apoptosis Cancer
    Lexibulin (CYT-997) is a potent and orally active tubulin polymerisation inhibitor with IC50s of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo . Lexibulin induces cell apoptosis and induces mitochondrial ROS generation in GC cells .
    Lexibulin
  • HY-111208
    CCT129957

    		Phospholipase Cancer
    CCT129957 is an indole derivative and a potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of ~3 μM and a GC50 of 15 μM. CCT129957 inhibits Ca 2+ release in squamous carcinoma cells at ~15 μM .
    CCT129957
  • HY-132184
    5,6-Epoxyeicosatrienoic acid

    5,6-EET; (±)5,6-EpETrE

    		 Adrenergic Receptor Calcium Channel Endocrinology
    5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
    5,6-Epoxyeicosatrienoic acid
  • HY-108741A
    Plecanatide acetate

    		Guanylate Cyclase Inflammation/Immunology Cancer
    Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis .
    Plecanatide acetate
  • HY-N6651
    Isocryptotanshinone

    		STAT Phosphatase Apoptosis Autophagy p38 MAPK EGFR JAK Bcl-2 Family Survivin Akt mTOR PARP Caspase Atg8/LC3 CDK Cancer
    Isocryptotanshinone is a dual STAT3 and PTP1B (IC50 = 56.1 μM) inhibitor. Isocryptotanshinone inhibits STAT3 by binding to the STAT3 SH2 domain to block phosphorylation and nuclear translocation [1][2]. Isocryptotanshinone exerts its anti-proliferative effect via the induction of cell cycle arrest, apoptosis, and pro-death autophagy, through the regulation of STAT3, AKT/mTOR and MAPK signaling pathways. Isocryptotanshinone suppresses the xenograft gastric cancer (GC) tumor growth in BALB/c nude mice. Isocryptotanshinone can be used for cancer research, such as lung cancer, breast cancer and GC .
    Isocryptotanshinone
  • HY-149453
    MCUF-651

    		Guanylate Cyclase Cardiovascular Disease
    MCUF-651 is an orally active guanylyl cyclase A receptor (GC-A) positive allosteric modulator (PAM) (KD: 397 nM ). MCUF-651 binds to GC-A and selectively enhances the binding of atrial natriuretic peptide (ANP) to GC-A. MCUF-651 enhances ANP-mediated cGMP generation in human cardiac, renal, and fat cells. MCUF-651 inhibits cardiomyocyte hypertrophy .
    MCUF-651
  • HY-114043
    NCGC00092410

    		Glycosidase Metabolic Disease
    NCGC00092410 is a potent, selective, and nonsugar glucocerebrosidase (GC) inhibitor, with an IC50 of 31 nM. NCGC00092410 shows no activity against the related hydrolases at concentrations up to 77 μM. NCGC00092410, a GC chaperone, and increases the activity and lysosomal localization of glucocerebrosidase in mutant cell lines. NCGC00092410 can be used for the research of Gaucher disease .
    NCGC00092410
  • HY-P991571
    GC1118

    GC-1118A

    		 EGFR PERK Akt Cancer
    GC1118 (GC-1118A) is a fully human anti-EGFR monoclonal antibody with binding affinity of 0.16 nM (KD) to EGFR. GC1118 displays potent inhibitory effects on high- and low-affinity EGFR ligand-induced signaling. GC1118 shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells. GC1118 can reach the tumor by crossing both BBB (blood-brain barrier) and BTB (brain-tumor barrier) and shows superior anti-tumor effects in various mice xenograft models. GC1118 can be used for the researches of cancer, such as colorectal cancer .
    GC1118
  • HY-14823G
    Sobetirome

    GC-1; QRX-431

    		 Thyroid Hormone Receptor Metabolic Disease Endocrinology
    Sobetirome (GMP) is Sobetirome (HY-14823) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Sobetirome (GC-1) is a thyroid hormone receptor β (TRβ)-specific agonist which bind selectively to TRβ-1 with an EC50 of 0.16 μM .
    Sobetirome
  • HY-114577
    Palifosfamide tromethamine
    2 Publications Verification

    Isophosphoramide mustard tromethamine; IPM tromethamine; ZIO-201 tromethamine

    		 DNA Alkylator/Crosslinker Cancer
    Palifosfamide (tromethamine) is a synthetic alkylating agent with potential antineoplastic activity. As the stabilized active metabolite of ifosfamide, palifosfamide (tromethamine) irreversibly alkylates and crosslinks DNA through GC base pairs. This leads to an inhibition of DNA replication and ultimately cell death. Compared to ifosfamide, palifosfamide (tromethamine) is less toxic.
    Palifosfamide tromethamine
  • HY-131389
    Cholesteryl heptadecanoate

    		Biochemical Assay Reagents Others
    Cholesteryl heptadecanoate is a cholesteryl ester internal standard that accurately determines the concentration of free cholesterol in cells without hydrolyzing triglycerides. Cholesteryl heptadecanoate can be used for the quantitative determination of cholesteryl esters by GC or LC mass spectrometry .
    Cholesteryl heptadecanoate
  • HY-P0118A
    Disitertide TFA

    P144 TFA

    		 TGF-beta/Smad PI3K Apoptosis Cancer
    Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer .
    Disitertide TFA
  • HY-10498A
    Lexibulin dihydrochloride

    CYT-997 dihydrochloride

    		 Microtubule/Tubulin Reactive Oxygen Species (ROS) Apoptosis Cancer
    Lexibulin dihydrochloride (CYT-997 dihydrochloride) is a potent and orally active tubulin polymerisation inhibitor with IC50s of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo . Lexibulin dihydrochloride induces cell apoptosis and induces mitochondrial ROS generation in GC cells .
    Lexibulin dihydrochloride
  • HY-P991582
    BI-1607

    		Fc Receptor (FcR) Cancer
    BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
    BI-1607
  • HY-P10786
    LinTT1 peptide

    		Transmembrane Glycoprotein Cancer
    LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. LinTT1 peptide targets peritoneal carcinoma (PC) by binding to the p32 (gC1qR) receptor. It can conjugate with iron oxide nanoworms (NWs) to form a nanocarrier. This nanocarrier is taken up by peritoneal carcinoma cells in vitro and enters the mitochondria; it also exhibits significant tumor targeting and penetration effects in mice. Moreover, LinTT1-functionalized nanocarriers, combined with the pro-apoptotic peptide [D(KLAKLAK)2], show significant tumor suppression in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery carrier for peritoneal cancer research .
    LinTT1 peptide
  • HY-162293
    CDK8-IN-14

    		CDK Cancer
    CDK8-IN-14 (compound 12) inhibits CDK8 with an IC50 value of 39.2 nM and has anti-AML cell proliferation activity (molm-13 GC50 = 0.02±0.01μM, MV4-11 GC50 = 0.03±0.01μM) .
    CDK8-IN-14
  • HY-156020
    Glucocerebrosidase-IN-2

    		Glycosidase Metabolic Disease
    Glucocerebrosidase-IN-2 (compound 12) is a quinazoline analogue and an inhibitor of glucocerebrosidase (GC). Glucocerebrosidase-IN-2 has the potential to improve GC translocation to lysosomes in Gaucher disease patient-derived cells (mostly carrying the N370S mutation). Glucocerebrosidase-IN-2 inhibits the hydrolysis of 4-methylumbelliferone β-D-glucopyranoside (4MU) and fluorescent glycosylceramide (FlourGC) in N370S mutant tissues with an AC50 of 25.29 μM .
    Glucocerebrosidase-IN-2
  • HY-10498R
    Lexibulin (Standard)

    CYT-997 (Standard)

    		 Reference Standards Microtubule/Tubulin Reactive Oxygen Species (ROS) Apoptosis Cancer
    Lexibulin (Standard) is the analytical standard of Lexibulin. This product is intended for research and analytical applications. Lexibulin (CYT-997) is a potent and orally active tubulin polymerisation inhibitor with IC50s of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo . Lexibulin induces cell apoptosis and induces mitochondrial ROS generation in GC cells .
    Lexibulin (Standard)
  • HY-P991482
    ADI-42898

    		Influenza Virus Infection
    ADI-42898 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    ADI-42898
  • HY-W040129R
    Chromomycin A3 (Standard)

    		Reference Standards Bacterial Fungal Apoptosis Antibiotic Infection Neurological Disease Cancer
    Chromomycin A3 (Standard) is the analytical standard of Chromomycin A3 (HY-W040129). This product is intended for research and analytical applications. Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg 2+. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .
    Chromomycin A3 (Standard)
  • HY-146398
    AMPK activator 6

    		AMPK Metabolic Disease
    AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
    AMPK activator 6
  • HY-W127512R
    5β-Cholanic acid (Standard)

    		Drug Intermediate Reference Standards Others
    5β-Cholanic acid is a hydrophobic modifier used to modify polymer carriers. 5β-Cholanic acid can improve the acid stability, cell penetration efficiency and drug sustained release ability of nanocarriers, and optimize the oral effectiveness of delivered molecules. 5β-Cholanic acid can covalently bind to Glycol chitosan (GC) to form a GC-CA conjugate, which optimizes the hydrophobic anchoring ability of nanoparticles and enables them to be stably adsorbed on the surface of PLGA nanoparticles. Such nanoparticles can resist dissociation in the gastric acid environment and maintain positive charge to enhance endocytic uptake by intestinal epithelial cells (such as Caco-2 cells). 5β-Cholanic acid can be used in the development of drug delivery systems .
    5β-Cholanic acid (Standard)
  • HY-DY1099
    7-Aminoactinomycin D (solution)

    7-AAD (solution)

    		 DNA/RNA Synthesis DNA Stain Bacterial Antibiotic Cancer
    7-Aminoactinomycin D (solution) (7-AAD (solution)) a cell-impermeant fluorescent DNA stain, is a potent RNA polymerase inhibitor. 7-Aminoactinomycin D selectively binds to GC regions of the DNA. 7-Aminoactinomycin D also has antibacterial effects .
    Solvent and concentration: DMSO: 1 mg/mL
    7-Aminoactinomycin D (solution)
  • HY-108628R
    SU16f (Standard)

    		Reference Standards PDGFR Cancer
    SU16f (Standard) is the analytical standard of SU16f (HY-108628). This product is intended for research and analytical applications. SU16f is a potent and selective PDGFRβ inhibitor with IC50s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, VEGF-R2, FGF-R1, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .
    SU16f (Standard)
  • HY-179535
    Axl-IN-21

    		TAM Receptor Discoidin Domain Receptor TGF-β Receptor Hedgehog Cancer
    Axl-IN-21 is an orally active and selective AXL inhibitor (Kd = 2.7 nM, IC50 = 4.0 nM). Axl-IN-21 displays kinase selectivity and retains strong activity against cancer-related mul-kinases (Mer with Kd = 1.4 nM, DDR1 with IC50 = 22.2 nM, HIPK4 with Kd = 11.0 nM and LOK with Kd =10 nM). Axl-IN-21 overcomes tumor microenvironment-driven resistance by blocking CAF-derived GAS6-induced AXL/STAT3/ABCG1 signaling, restoring chemosensitivity and inhibiting drug efflux in gastric cancer (GC). Axl-IN-21 suppresses TGF-β1-induced epithelial-mesenchymal transition (EMT), migration, and invasion in MDA-MB-231 cells. Axl-IN-21 exhibits no significant cytotoxicity in non-cancerous cells. Axl-IN-21 can be research for triple negative breast cancer and gastric cancer [1] [2] .
    Axl-IN-21

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: